MX371068B - ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. - Google Patents
((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma.Info
- Publication number
- MX371068B MX371068B MX2016016751A MX2016016751A MX371068B MX 371068 B MX371068 B MX 371068B MX 2016016751 A MX2016016751 A MX 2016016751A MX 2016016751 A MX2016016751 A MX 2016016751A MX 371068 B MX371068 B MX 371068B
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline
- methyloxime
- pyrrolidin
- biphenyl
- hydroxymethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Se proporciona (3Z,5S).5.(hidroximetil)-1-[(2'-metil-1,1'-bifenil- 4-il)carnonil]pirrolidin-3-ona O -metiloxima cristalina. También se describe una composición farmacéutica que contiene el compuesto cristalino y métodos para tratar condiciones relacionadas con la actividad de OT-R, como por ejemplo, parto pretérmino y para incrementar la tasa de implantación de un embrión en un mamífero que experimenta transferencia de embriones, que comprende administrar el compuesto cristalino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020076P | 2014-07-02 | 2014-07-02 | |
| PCT/EP2015/062881 WO2016000920A1 (en) | 2014-07-02 | 2015-06-10 | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016751A MX2016016751A (es) | 2017-08-08 |
| MX371068B true MX371068B (es) | 2020-01-15 |
Family
ID=53434312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016751A MX371068B (es) | 2014-07-02 | 2015-06-10 | ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9718772B2 (es) |
| EP (2) | EP3753921A1 (es) |
| JP (4) | JP2017519015A (es) |
| KR (1) | KR102470283B1 (es) |
| CN (3) | CN114105851A (es) |
| AU (1) | AU2015283133B2 (es) |
| CA (1) | CA2953722C (es) |
| EA (2) | EA031353B1 (es) |
| ES (1) | ES2774789T3 (es) |
| IL (1) | IL249652B (es) |
| MX (1) | MX371068B (es) |
| UA (1) | UA122210C2 (es) |
| WO (1) | WO2016000920A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| MX371068B (es) | 2014-07-02 | 2020-01-15 | ObsEva SA | ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. |
| WO2017118639A1 (en) | 2016-01-04 | 2017-07-13 | ObsEva S.A. | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| AU2017300026B2 (en) | 2016-07-21 | 2023-07-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| JP7584201B2 (ja) | 2019-09-03 | 2024-11-15 | オブセヴァ エス．エー． | 薬学的組成物 |
| JP7083793B2 (ja) * | 2019-09-10 | 2022-06-13 | Ｊｆｅケミカル株式会社 | パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法 |
| CA3167121A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU120988A (en) | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| YU183988A (en) | 1988-09-30 | 1990-08-31 | Lek Tovarna Farmacevtskih | Process for preparing dispersion pills of dihydroergotoxine |
| US5089043A (en) | 1989-11-09 | 1992-02-18 | Shionogi & Co., Ltd. | Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides |
| US5889001A (en) | 1993-07-29 | 1999-03-30 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| JP3534903B2 (ja) | 1995-06-09 | 2004-06-07 | 鐘淵化学工業株式会社 | １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法 |
| GB9603699D0 (en) | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| RU2246294C2 (ru) | 1999-12-09 | 2005-02-20 | Дзе Бутс Компани ПЛС | Терапевтические средства |
| WO2001072705A1 (en) | 2000-03-27 | 2001-10-04 | Applied Research Systems Ars Holding N.V. | Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| EP1268418B1 (en) | 2000-03-27 | 2006-06-14 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| DE60124405T2 (de) | 2000-07-14 | 2007-02-22 | Nitto Denko Corp., Ibaraki | Reinigungsblatt, förderelement dafür und reinigungsverfahren für substrat-bearbeitungsvorrichtungen in dem diese verwendet werden |
| EP1829861A3 (en) | 2001-03-20 | 2009-01-21 | Laboratoires Serono SA | Pyrrolidine ester derivatives active as oxytocin antagonists |
| KR200245627Y1 (ko) * | 2001-05-15 | 2001-10-15 | 김병두 | 전기 가열부재가 부착된 냄비 |
| US7115639B2 (en) | 2001-06-18 | 2006-10-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists |
| JP2003192582A (ja) | 2001-12-12 | 2003-07-09 | Merck Patent Gmbh | ナプロキセンナトリウムを含む速放性錠剤 |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| AU2004215661B2 (en) | 2003-02-27 | 2009-12-03 | Merck Serono Sa | Pyrrolidine derivatives as oxytocin antagonists |
| DE602005003803T2 (de) | 2004-02-26 | 2008-12-24 | Laboratoires Serono S.A., Coinsins | Verfahren zur herstellung von pyrrolidinoximen |
| GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| ES2366130T3 (es) | 2005-05-10 | 2011-10-17 | Ferring B.V. | Uso de antagonistas de oxitocina y/o vasopresina en reproducción asistida. |
| JP2008189732A (ja) | 2007-02-01 | 2008-08-21 | Fujifilm Corp | セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置 |
| PL2572705T3 (pl) | 2007-10-01 | 2018-01-31 | Lesvi Laboratorios Sl | Tabletki ulegające rozpadowi w jamie ustnej |
| US9201077B2 (en) | 2009-07-27 | 2015-12-01 | Colorado State University Research Foundation | Direct enzyme immunoassay for measurement of serum progesterone levels |
| WO2014080032A1 (en) | 2012-11-26 | 2014-05-30 | Ferring B.V. | Method and system for diagnosing uterine contraction levels using image analysis |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| MX371068B (es) | 2014-07-02 | 2020-01-15 | ObsEva SA | ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. |
| PL3037101T3 (pl) | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
-
2015
- 2015-06-10 MX MX2016016751A patent/MX371068B/es active IP Right Grant
- 2015-06-10 CN CN202111229040.XA patent/CN114105851A/zh active Pending
- 2015-06-10 EP EP19204954.2A patent/EP3753921A1/en active Pending
- 2015-06-10 US US14/735,215 patent/US9718772B2/en active Active
- 2015-06-10 CN CN201580047177.XA patent/CN106795110A/zh active Pending
- 2015-06-10 AU AU2015283133A patent/AU2015283133B2/en active Active
- 2015-06-10 JP JP2016573776A patent/JP2017519015A/ja active Pending
- 2015-06-10 WO PCT/EP2015/062881 patent/WO2016000920A1/en active Application Filing
- 2015-06-10 EA EA201790080A patent/EA031353B1/ru unknown
- 2015-06-10 UA UAA201700678A patent/UA122210C2/uk unknown
- 2015-06-10 CA CA2953722A patent/CA2953722C/en active Active
- 2015-06-10 ES ES15730094T patent/ES2774789T3/es active Active
- 2015-06-10 KR KR1020177001267A patent/KR102470283B1/ko active IP Right Grant
- 2015-06-10 EA EA201891873A patent/EA201891873A1/ru unknown
- 2015-06-10 EP EP15730094.8A patent/EP3164384B1/en active Active
- 2015-06-10 CN CN202111228955.9A patent/CN114105850A/zh active Pending
-
2016
- 2016-12-19 IL IL249652A patent/IL249652B/en unknown
-
2017
- 2017-05-25 US US15/604,816 patent/US10752583B2/en active Active
-
2020
- 2020-11-09 JP JP2020186785A patent/JP2021038236A/ja active Pending
-
2022
- 2022-11-18 JP JP2022184804A patent/JP2023018037A/ja active Pending
-
2024
- 2024-10-18 JP JP2024182585A patent/JP2025013885A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL249652A0 (en) | 2017-02-28 |
| JP2023018037A (ja) | 2023-02-07 |
| UA122210C2 (uk) | 2020-10-12 |
| KR102470283B1 (ko) | 2022-11-23 |
| IL249652B (en) | 2021-09-30 |
| CN114105850A (zh) | 2022-03-01 |
| AU2015283133A1 (en) | 2017-02-16 |
| MX2016016751A (es) | 2017-08-08 |
| CA2953722A1 (en) | 2016-01-07 |
| KR20170023961A (ko) | 2017-03-06 |
| JP2017519015A (ja) | 2017-07-13 |
| CN114105851A (zh) | 2022-03-01 |
| EP3164384A1 (en) | 2017-05-10 |
| EP3164384B1 (en) | 2019-12-04 |
| US20170320822A1 (en) | 2017-11-09 |
| AU2015283133B2 (en) | 2019-05-16 |
| US9718772B2 (en) | 2017-08-01 |
| CN106795110A (zh) | 2017-05-31 |
| US20160002160A1 (en) | 2016-01-07 |
| EA031353B1 (ru) | 2018-12-28 |
| WO2016000920A1 (en) | 2016-01-07 |
| EP3753921A1 (en) | 2020-12-23 |
| EA201891873A1 (ru) | 2019-04-30 |
| US10752583B2 (en) | 2020-08-25 |
| ES2774789T3 (es) | 2020-07-22 |
| JP2025013885A (ja) | 2025-01-28 |
| EA201790080A1 (ru) | 2017-06-30 |
| JP2021038236A (ja) | 2021-03-11 |
| CA2953722C (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX371068B (es) | ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2018005620A (es) | Composiciones que comprenden un inhibidor de demetilasa-1 especifico de lisina. | |
| MX2019003598A (es) | Formulaciones orales de derivados de pirrolidina. | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| TN2018000188A1 (en) | Isoindole compounds | |
| CR20180056A (es) | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil] [3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| MD4780B1 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
| MX2022014763A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| PH12016502568A1 (en) | Novel heterocyclic compound | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| TW201613921A (en) | Serine derivatives as ghrelin receptor agonists | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| RU2014104644A (ru) | Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |